ArticleFrontiers in genetics2020
Multi-Omics Analysis of Diabetic Nephropathy Reveals Potential New Mechanisms and Drug Targets.
Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Bibliometrics and visualization analysis: Big data research on diabetic kidney disease from 2000 to 2025.Medicine · 2026Article
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- The Need for Omics Studies in Chronic Kidney Disease of Unknown Etiology (CKDu): A Narrative Review and Perspective.International journal of molecular sciences · 2026Review
- Renal and metabolic effects of semaglutide plus canagliflozinWorld journal of diabetes · 2026Article
- Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery.International journal of molecular sciences · 2026Review
- The lipid-podocyte axis: emerging clues in membranous nephropathy pathogenesis.Frontiers in medicine · 2026Review
- Foodomics in Diabetes Management: A New Approach.Food science & nutrition · 2025Review
- The effect of Zuogui-Jiangtang-Yishen decoction on the intestinal flora's response to L-α-phosphatidylcholine and L-tyrosine in patients with diabetic kidney disease: anFrontiers in pharmacology · 2025Article
- A human stem cell-derived model reveals pathologic extracellular matrix remodeling in diabetic podocyte injury.Matrix biology plus · 2024Article
- Steps to understanding diabetes kidney disease: a focus on metabolomics.The Korean journal of internal medicine · 2024Review
- To Develop Biomarkers for Diabetic Nephropathy Based on Genes Related to Fibrosis and Propionate Metabolism and Their Functional Validation.Journal of diabetes research · 2024Article
- CRTC2 activates the epithelial-mesenchymal transition of diabetic kidney disease through the CREB-Smad2/3 pathway.Molecular medicine (Cambridge, Mass.) · 2023Article
- Application of Metabolomics and Traditional Chinese Medicine for Type 2 Diabetes Mellitus Treatment.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Network-based identification and prioritization of key transcriptional factors of diabetic kidney disease.Computational and structural biotechnology journal · 2023Article
- MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro.Cells · 2022Article
- Advances in proteomic profiling of pediatric kidney diseases.Pediatric nephrology (Berlin, Germany) · 2022Review
- Untargeted Metabolomic Plasma Profiling of Emirati Dialysis Patients with Diabetes versus Non-Diabetic: A Pilot Study.Biomolecules · 2022Article
- Majorbio Cloud: A one-stop, comprehensive bioinformatic platform for multiomics analyses.iMeta · 2022Article
- Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone.Proteomes · 2022Review
- Implications of Sphingolipid Metabolites in Kidney Diseases.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is one of the most common diabetic complications, which is the major course of end-stage renal disease (ESRD). However, the systematical molecular characterizations during DN pathogenesis and progression has not been not well understood. To identify the fundamental mediators of the pathogenesis and progression of DN. we performed a combination RNASeq, proteomics, and metabolomics analyses of both patients' derived kidney biopsy samples and kidneys from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.